SPONSORED

Medical Device Company, BioSig Technologies Inc. Has Hearts Pumping in a Potential $8.5 Billion Market(1)

The Top 5 Reasons BioSig Technologies U.S. NASDAQ: (BSGM) Could Soar in 2021 and Beyond

  1. An estimated 12.1 million people in the United States could have AFib in 2030.(2) The market for BioSig’s PURE EP technology could also be $4.6 billion while growing at approximately 10% a year. Over the next four years, it may also increase to $8.5 billion.(1)
  2. 3 significant hedge funds, including Citadel Investment Group, are quietly snapping up shares of BSGM.(3)
  3. BioSig could get HUGE market exposure as presenters at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat.(4)
  4. On BSGM skyrocketed 15.56% on 167% higher volume closing above the 50-day moving average on June 28th, 2021.(5)
  5. BioSig has a noteworthy 10-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures.(6)

Most of us are familiar with an arrhythmia.

It’s a glitch in the heart’s rhythm created by electric impulses, which coordinate heartbeats. Roughly four million Americans deal with this issue every year.(5)

“Two of the most prevalent, complex and potentially deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT). Ventricular arrhythmias account for approximately 300,000 sudden deaths per year in the United States alone. Catheter ablation is fast becoming a first line therapy, driving demand for improved technologies. AF is the most common arrhythmia affecting 33.5 million people worldwide, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately $6B annually; adding other indirect costs brings AF total cost to $26B.”(9)

As also noted by the AHA, what could help these millions of patients may be increased awareness and better diagnostic tools. Results can potentially help a doctor decide if you need medication, a pacemaker, a defibrillator, or cardiac ablation.

Fortunately, medical technology companies like BioSig Technologies Inc. U.S. NASDAQ: (BSGM) exist to potentially make this happen and revolutionize the process.

BioSig is a company commercializing a biomedical signal processing platform designed to improve electrophysiology (EP). The company’s PURE EP is a computerized system designed to reveal the full range of cardiac signals and provide physicians with signal clarity during procedures to address cardiac arrhythmias. To date, physicians using the PURE EP System have successfully completed over 350 patient cases.(15)

The company also has a noteworthy 10-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures.(6)

BioSig Technologies could be in an excellent position to take advantage of the $4.6 billion electrophysiology market. A market that’s growing at more than approximately 10.4% annually and expected to nearly double to $8.5 billion in the next four years.(1)

BioSig Technologies Inc. U.S. NASDAQ: (BSGM)- A Stock With Explosive Promise Causing Hedge Funds To Rush In

On June 28, 2021, alone, BioSig Technologies skyrocketed 15.56% from $3.60 to $4.16 on an incredible 167% increase in volume. The daily average on volume, which sat at 282,917 on the same date, screamed higher to 755,824 in a single day.(5)

Plus, the stock blasted through double resistance of $3.55 to close above the 50-day moving average. This could signal a big pivot or trend reversal to the upside. The stock’s all-time high is $11.55, giving it plenty of possible room to run.

How much higher could it go?

As a potential result, 3 significant hedge funds have taken notice. They are beginning to pile in(3) – perhaps because they believe the company could be a solid acquisition target?


For one, Citadel Investment Group, LLC is a Hedge Fund that gave a resounding YES to BSGM. Citadel is one of the world’s largest alternative asset managers, with more than US$35 billion in assets under management (as of October 1, 2020). They took a stake worth $0.7 million reported as of the end of March.(3)

Why is any investment from Citadel potentially a huge deal? During the health predicament, Citadel doubled its profit. It earned $4 billion in revenue during the first half of 2020 due to increased volatility and retail trading. In other words, when Citadel makes a move as drastic as what they did with BioSig, it might be wise to pay close attention.(14)

In addition, BioSig boasts a solid balance sheet, a rapidly increasing user base, and no debt.(7)(8)

Here’s Why PURE EP Could Be a Game-Changer

As we mentioned earlier, BioSig’s PURE EP device is a computerized system designed to reveal the full range of cardiac signals. All while providing physicians with signal clarity during procedures performed to address cardiac arrhythmias.

According to XTalks, PURE EP could fill a significant need because:

“The electrograms used today can be riddled with noise and artifacts coming from other equipment found in the operating room. Such a procedure can take up to six hours, potentially yielding what is referred to in the industry as a ‘dirty signal’ that’s indiscernible to interpret by many electrophysiologists.”(10)

BioSig’s PURE EP was developed to address unmet needs in a large and growing market and deliver technology to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation, and Ventricular Tachycardia.

“The system is intended to acquire, digitize, amplify, filter, measure and calculate, display, record and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data,” as further reported XTalks.(10)

Furthermore, BioSig Technologies’ PURE EP system has:(11)

  • A signal processing platform designed to reveal the full range of cardiac signals and provide electrophysiologists with signal clarity during procedures.
  • The ability to refine signal clarity by reducing signal noise with higher precision.
  • The potential to allow surgeons to work far more accurately, decreasing the probability of a repeat procedure and increasing procedure safety.

Even more impressive, the PURE EP Systems are already installed at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic’s Florida campus, Massachusetts General Hospital, the University of Pennsylvania, and Deborah Heart and Lung Center.(12)

Meet BioSig Technologies’s U.S. NASDAQ: (BSGM) World-Class Leadership

BioSig is led by a team of experienced professionals and experts and overseen by a board of directors with decades of experience working with blue-chip brands and startups. Together, this team brings a distinctive skill set to managing and growing the company.

BioSig’s founder and CEO, Ken Londoner, has a proven track record as a business entrepreneur, a biomedical executive, and an investment expert. His career highlights include founding Safe Port Holdings, which was sold for 6x investments; serving as EVP for New Cardio, a Silicon Valley cardiac software company; and founding Red Coat Capital Management, which grew from $2 million to more than $1 billion in assets.

The other members of the company’s small but growing executive team have solid credentials in their respective areas of expertise, including management experience at top global companies.

Likewise, the advisory board members bring decades of private- and public-sector experience in relevant fields such as healthcare, life sciences, technology, and capital markets.

Lastly, BioSig’s board of directors comprises executives who have worked at some of the largest and most influential medical device companies, such as Johnson & Johnson and Boston Scientific. Several board members also have capital market and investment experience from leading institutions such as Nasdaq and Wilmington Trust. Rounding the rest of the board out are leaders of healthcare startups and emerging growth companies.

Leadership Team

Kenneth L. Londoner, MBA
Founder, Chief Executive Officer, Chairman, and Director

Mr. Londoner is a capital markets and capital architecture expert and a senior life science executive. Having started his career as a research analyst for J. & W. Seligman & Co., Inc., a leading institutional money management firm in New York City, NY, he quickly found himself at the forefront of the biotech industry in the early 1990s, leading him to manage $3.5 billion in mutual and pension funds and international assets.

His passion for medical innovation led him to co-found, govern and bring to the public market a number of life science companies, including BioSig Technologies, Inc. [Nasdaq:BSGM]. Working in close collaboration with key opinion leaders in electrophysiology, BioSig aims to improve the outcomes of cardiac ablations for the treatment of arrhythmias through novel technological solutions developed by the company, and further apply its core competency in advanced biomedical signal processing and analysis to other areas of medicine.

His prior experience in recognizing the early potential of biotech led Londoner to form the Alliance for Advancing Bioelectronic Medicine, an independent non-profit network of professionals dedicated to innovation at the intersection of healthcare and technology. The Alliance aims to increase awareness of bioelectronic medicine and build a platform for collaboration among stakeholders. Over the last decade, Londoner formed top level relationships with a number of medical centers of excellence such as Mayo Clinic, NYU Langone Hospital and UCLA, as well as other stakeholders, including investment communities, intellectual property experts and supply chain partners.

Steve Chaussy
Chief Financial Officer

Mr. Chaussy has served as Chief Financial Officer of BioSig Technologies, Inc., since May of 2011, making him one of the Company’s most veteran executives. He brings an impressive array of professional experiences, detailed protocols, and an adept understanding of the financial operations of public companies.

Mr. Chaussy has an extensive entrepreneurial growth and development background from working for Penske Truck Leasing Co., L.P., a Penske Corporation subsidiary, where his improvements of management and reporting tools allowed the Company to double in size. Since 2005, Mr. Chaussy has been the sole proprietor of Anna & Co., Inc., a consulting company that offers services to small publicly traded companies. Anna & Co., Inc. provides general financial and accounting services, emphasizing SEC reporting and compliance, to companies that lack sufficient resources to hire full-time employees to offer such services. From 2001 to 2005, Mr. Chaussy provided services as both a Chief Financial Officer and a consultant to small publicly traded companies. Before 2001, Mr. Chaussy served as the chief financial officer for a large private distribution and wholesaling Company, where he gained international experience.

Mr. Chaussy is a graduate of Virginia Polytechnic Institute and State University and is a licensed, certified public accountant in Virginia, California, and Florida.

Natasha Drapeau
Executive Vice President

Natasha Drapeau has been with BioSig Technologies, Inc. since May of 2017 and is primarily responsible for leading Company operations. Based in Geneva, Switzerland, Ms. Drapeau is BioSig’s primary executive for future European operations. She works closely with the Board of Directors and strategic partners, including medical centers of excellence and IP advisors. Ms. Drapeau serves as President at NeuroClear, Inc., Executive Vice President at BioSig Technologies, Inc., and is a founding member of the Alliance for Advancing Bioelectronic Medicine.

Ms. Drapeau brings over 18 years of international business development experience, including more than nine years at IG Group Plc, a leading British FTSE 250 financial services company. While working for IG, she was responsible for the Group’s global business development, including a worldwide rebranding and business support to 16 international offices in Europe, South Africa, Singapore, and Australia.

Mrs. Drapeau holds two MSc degrees with honors in Management and German from Samara Academy of Economics, as well as a Business, International Relations, and Political Economy degree from The London School of Economics. Mrs. Drapeau is a member of the Institute of Directors in the United Kingdom.

Dr. Barry Keenan, Ph.D., MBA, PMP
Vice President, Engineering

Dr. Keenan has been with BioSig Technologies, Inc. since March of 2019, and brings to the Company over 20 years of industry experience. He is a subject matter expert in R&D, product development and commercialization, neuromodulation, deep brain stimulation, sensing, imaging, and cardiac pacing. A biomedical engineer by training, Dr. Keenan spent over nine years at Medtronic Diabetes. He was responsible for all algorithm development and successfully developed the MiniMedTM ParadigmTM VeoTM and iProTM2 Professional Continuous Glucose Monitoring (CGM). One of Dr. Keenan’s career highlights was the development and successful clinical evaluation of the MiniMedTM 670G, the world’s first artificial pancreas. This invention became one of the top revenue-generating products for Medtronic. The research was featured in Time magazine’s 25 Best Inventions of 2013 and 2016 and named one of the Best Medical Technologies of 2016.

Since 2014, Dr. Keenan has been actively involved with the Alfred Mann Foundation for Scientific Research as CTO, Vice President of Research & Development, and Board member. During Dr. Keenan’s engagement with the Foundation, he managed an R&D department of over 40 scientists and engineers consisting of software, firmware, electrical, mechanical, and ASIC groups developing innovative medical devices, implanted neuromodulation, and sensing systems.

Dr. Keenan is a winner of several awards and is a Medtronic Technical Fellow. His team at Medtronic won Technical Contributors of the Year for their work in the Artificial Pancreas, which also achieved ‘Best of What’s New’ in Popular Science’s health category. Dr. Keenan is an inventor of 39 patents and authored over 30 scientific manuscripts and book chapters.

Dr. Keenan has a B.A. in Electrical and Electronics Engineering from University of Ulster, an MBA from Queens University, a Ph.D. in Biomedical/Medical Engineering from University of Ulster, a Doctoral Research degree from University of Michigan, and an MBA from Cornell University.

Brenda Castrodad
Director of Human Resources

A seasoned executive, Ms. Castrodad brings a wealth of experience in leading organizational development in start-ups and Fortune 500 companies within the life sciences sector. Most recently, Ms. Castrodad led the HR department at TissueTech, Inc., a Miami, FL-based biotech leader in regenerative amniotic tissue-based products, where she was responsible for transformation and automation of the company’s HR practices, talent planning, and team building. Prior to TissueTech, Inc., Ms. Castrodad spent six years at HeartWare, Inc., a heart failure medtech company acquired by Medtronic [NYSE:MDT] in 2016 for $1.1 billion. By optimizing the internal talent acquisition function and aligning business practices, Ms. Castrodad helped grow the organization from approx. 80 to 500+ staff which achieved approx. $250 million in revenues before the acquisition. Earlier in her career, Ms. Castrodad spent 16 years at Schering-Plough Corp, a pharmaceutical company acquired in 2009 for $41.1 billion by Merck & Co. [NYSE:MRK]. Ms. Castrodad holds a Master’s Degree in Public Administration and a Bachelor’s Degree in Social Sciences – Human Welfare from the University of Puerto Rico and a Labor Relations Certificate from the University of Michigan.

Andrew Ballou
Vice President, Investor Relations

Mr. Ballou brings to BioSig over 25 years of experience in capital markets, including institutional equity sales and research analysis. Most recently, Mr. Ballou served as Managing Director, Head of Institutional Equity Sales at Janney Montgomery Scott LLC., a role in which he oversaw key accounts, including large multi-manager hedge funds, mutual funds and dedicated sector funds. Prior to that role Mr. Ballou managed selected key account coverage at RBC Capital Markets, including Millennium Partners, Soros Fund Management, SIR Capital, Columbia Threadneedle, Two Sigma Investments and Times Square Capital Management. During the course of his career Mr. Ballou analyzed various private and public companies in healthcare, media and retail sectors. Mr. Ballou graduated from Hampden-Sydney College, Virginia, with a Bachelor of Arts in English.

John Kowalski
Vice President, Sales

Mr. Kowalski brings to the Company over 30 years of experience in medical device sales, including over 20 years at Biosense Webster, a Johnson & Johnson company. Most recently, he served as Northeast Area Director, a role, in which he was responsible for leading six high-performing cardiac electrophysiology catheter and equipment market sales teams, consisting of 140 sales and clinical support employees. Mr. Kowalski helped drive $175M of disposables and system sales and has consistently exceeded area sales objectives. Having led U.S. strategic planning teams in his previous roles, Mr. Kowalski brings to BioSig proven track record in identifying key business growth opportunities within the cardiac electrophysiology market.

Mr. Kowalski is a holder of numerous Biosense Webster leadership awards, including a record 18-year Founders Club Award, and several “Area and Region of the Year” awards.

Lora Mikolaitis
Vice President, Administration

As Vice President of Administration, Ms. Mikolaitis’ role encompasses a wide range of duties that began with co-writing the business plan to now co-writing marketing materials and SEC filings. She supports many of the departments of the Company including shareholder/investor/public relations, accounting/finance, legal, marketing, human resources, and research and development. Ms. Mikolaitis is also President of Miko Consulting Group, Inc., a firm that provides marketing research and administrative support to life science companies.

Julie Stephenson
Vice President, Clinical Affairs

Mrs. Stephenson brings to BioSig over 20 years of cardiac device technology experience having served in various clinical, sales, and marketing roles at Medtronic, Boston Scientific, and Guidant Corporation. Most recently, Mrs. Stephenson served as Director of Medical Education at Medtronic, a role in which she developed and delivered over 10 national peer-to-peer education programs annually and was responsible for numerous other supplemental educational resources for EP fellows. This work included collaboration with internationally recognized physician leaders. Other highlights of Mrs. Stephenson’s career with Medtronic included supervising the contracting and honoraria processes, serving as the Medical Education Liaison to Latin America, and participating in the Global Innovation Fellowship Program.

Earlier in her career, Mrs. Stephenson was the Regional Sales Manager with Boston Scientific in Central New Jersey for three years. During this time Mrs. Stephenson was responsible for driving meaningful sales revenues. Prior to this, she served as a Sales Representative and Field Clinical Representative with Guidant Corporation for 7 years.

A critical care nurse by training, Mrs. Stephenson holds a BSN degree from Northwestern State University and MBA from The Darden School of Business at University of Virginia. Mrs. Stephenson received numerous awards, including the President’s Club Award, Regional Sales Manager of the Year (New York Area), a Patent Award, and the Faculty Award.

Olivier Chaudoir
Senior Director of Marketing

Mr. Chaudoir brings to BioSig over 20 years of medical technology experience, including over 15 years in electrophysiology. Most recently, Mr. Chaudoir served as WW Senior Global Strategic Marketing Director at DePuy Synthes (a Johnson & Johnson company), a role, during which he led strategic competitive assessments in the sector of spinal enabling technologies and established a multi-generation technology roadmap and execution plan. Prior to it, Mr. Chaudoir spent 17 years at Biosense Webster in the U.S., France and Belgium. During this time, he progressed from the field clinical support roles to Atrial Fibrillation Specialist to Regional Business Director and successfully led the company’s operations in Northern and Southern California. One of the highlights of Mr. Chaudoir’s career include a successful global launch of CARTOÒ3 Navigation System. Mr. Chaudoir’s contributions to this product launch include development of innovative commercial marketing programs to enable customer acceptance for the US, Japanese and Chinese electrophysiology markets. Mr. Chaudoir is a holder of a Marketing Mastery Award (FUSE JNJ MD&D Global Surgery). He graduated from Pole Academique de Bruxelles (Belgium) school with the BSc degree in Biomedical Electronics Engineering and University of Sussex in the UK with a MSc degree in Digital Electronics and Parallel Processing Systems. Mr. Chaudoir completed The Berkeley Executive Leadership Program and is bilingual in French and English.

Manasi Patwardhan
Senior Director of Strategic Planning

Ms. Patwardhan brings to BioSig over 18 years of program management and product development experience with several Fortune 500 companies in the medical technology, pharma and healthcare verticals. A biomedical engineer by training, Ms. Patwardhan’s core competencies span manufacturing and vendor management, systems engineering, cross-functional team leadership and process improvements. Most recently, Ms. Patwardhan was in a technical program management role at Verily Life Sciences, LLC, an Alphabet, Inc. company, a role, in which she led hardware development for a class III therapy technology program as well as supply-chain and vendor management. Prior to that, Ms. Patwardhan was employed by Boston Scientific – Neuromodulation, where she was responsible for delivering a range of technology and product development programs, including commercially launched products in the Spinal Cord Stimulation portfolio as well as a connected health eco system. Earlier in her career Ms. Patwardhan was with Medtronic Diabetes, where she led product development efforts for class II therapy, diagnostic and combination products. Her work involved the delivery of engineering solutions from cross-functional teams comprising human factors, marketing, industrial design, hardware and software design and third-party vendors. Ms. Patwardhan holds a Master of Science in Biomedical Engineering from the University of Southern California Los Angeles and Bachelor of Engineering, Chemical Engineering from University of Pune, India.

Ewald Riechert
Director of Regulatory Affairs / Quality Assurance

With over 20 years of senior management experience in Fortune 500 companies, European notified bodies, and start-ups in the US, Europe, and Asia, Mr. Riechert is an expert in regulatory affairs. He has specialized experience in design controls and technical documentation and leads BioSig’s medical device compliance and quality assurance team.

Over the course of his impressive career, Mr. Riechert has achieved a host of medical device approvals, including 510(k) clearances, European CE markings, and other international clearances for a range of devices, including RF ablation generators, ablation catheters, and guidewires. Mr. Riechert served as a General Manager for TUV Rheinland for six years, where he managed three offices, working in Germany, the US, Japan, and Taiwan. His professional experience also includes serving as a Principal RA Consultant at Oriel Stat A Matrix, Director of Regulatory Affairs for Zeltiq Aesthetics, Inc., and Senior Manager for International Regulatory Affairs for Acclarent Inc (a J&J Company). Additionally, Mr. Riechert received professional training as an Electrical Energy Systems Technician at Dynamit Nobel, Troisdorf, Germany.

Mr. Riechert holds an MBA from the University of Phoenix and a BSEE from the University of Siegen, Germany.

Sasha Gentling, CFA
Director of Business Development and Investments

Prior to joining the Company, Ms. Gentling served as Investment Officer at Mayo Clinic, a role, in which she managed key components of Mayo Clinic’s investment portfolio, overseeing external manager relationships in absolute return core credit hedge fund strategies, fixed income, and real estate private equity, as well as conducting comprehensive due diligence on potential new investments in both public and private markets. Prior to that role Ms. Gentling managed investor communications and marketing activities at Connecticut based Discerene Group. During the course of her career Ms. Gentling conducted extensive research for emerging value-oriented hedge funds and generated investment recommendations by building and maintaining earnings, valuation models and financial projections. Ms. Gentling holds an MBA in Finance and Management from Columbia Business School and a BA in English and Music from Middlebury College.

Advisory Board

Sim Farar
Advisor

Dr. Ramachandra Malya, M.D.
Advisor

Kent Bennett Williams
Advisor

David-Andrew (D.A.) Wallach
Advisor

Frank J. Quintero
Advisor

Zachariah P. Zachariah, M.D.
Advisor

Anthony Amato
Advisor

Board of Directors

Kenneth L. Londoner, MBA
Founder, Chief Executive Officer, Chairman, and Director

Anthony Zook
Director

David Weild IV
Director

Donald E. Foley
Director

Jeffrey O’Donnell
Director

Patrick J. Gallagher
Director

Samuel E. Navarro
Director

The Top 5 Reasons BioSig Technologies U.S. NASDAQ: (BSGM) Could Soar in 2021 and Beyond

  1. An estimated 12.1 million people in the United States could have AFib in 2030.(2) The market for BioSig’s PURE EP technology could also be $4.6 billion while growing at approximately 10% a year. Over the next four years, it may also increase to $8.5 billion.(1)
  2. 3 significant hedge funds, including Citadel Investment Group, are quietly snapping up shares of BSGM.(3)
  3. BioSig could get HUGE market exposure as presenters at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat.(4)
  4. On BSGM skyrocketed 15.56% on 167% higher volume closing above the 50-day moving average on June 28th, 2021.(5)
  5. BioSig has a noteworthy 10-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures.(6)

Source 1 https://www.globenewswire.com/news-release/2021/06/25/2253372/0/en/Electrophysiology-Devices-Market-Size-to-Surpass-Around-US-10-72-Bn-by-2027.html
Source 2: https://www.cdc.gov/heartdisease/atrial_fibrillation.htm
Source 3: https://finance.yahoo.com/news/where-hedge-funds-stand-biosig-181413971.html
Source 4: https://finance.yahoo.com/news/biosig-signal-processing-technology-electrophysiology-134500015.html
Source 5: https://stockcharts.com/h-sc/ui
Source 6: https://www.globenewswire.com/news-release/2017/03/17/940598/22558/en/BioSig-Technologies-Announces-Strategic-Partnership-with-Mayo-Clinic.html
Source 7: https://ir.biosig.com/balance-sheet
Source 8: https://finance.yahoo.com/news/biosig-sees-increased-case-volume-222815099.html
Source 9: https://d1io3yog0oux5.cloudfront.net/_269b3834a20423d95470d6e4877b861e/biosigtech/db/338/2433/pdf/BioSig_Fact+Sheet_4.07.20_.pdf
Source 10: https://xtalks.com/biosigs-pure-ep-system-in-first-clinical-cases-1869/
Source 11: https://www.biosig.com/pure-ep/our-solution
Source 12: https://finance.yahoo.com/news/biosig-sees-increased-case-volume-222815099.html
Source 13: https://www.globenewswire.com/news-release/2017/03/17/940598/22558/en/BioSig-Technologies-Announces-Strategic-Partnership-with-Mayo-Clinic.html
Source 14: https://www.bloomberg.com/news/articles/2020-09-25/citadel-doubled-profit-increased-dominance-in-wild-2020-trading
Source 15: https://www.globenewswire.com/en/news-release/2020/11/30/2136750/22558/en/BioSig-s-PURE-EP-System-to-Support-Live-Patient-Cases-during-EPLive-2020.html#:~:text=Texas%20Cardiac%20Arrhythmia%20Institute%20

Legal Disclaimer


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

INFLUENCER COMPENSATION

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 12/11/2020 and ending on 12/11/2020 to publicly disseminate information about (BSGM:US) via digital communications. We have paid this Influencer six hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 12/14/2020 and ending on 12/14/2020 to publicly disseminate information about (BSGM:US) via digital communications. We have paid this Influencer one thousand three hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 12/15/2020 and ending on 12/15/2020 to publicly disseminate information about (BSGM:US) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 12/18/2020 and ending on 12/18/2020 to publicly disseminate information about (BSGM:US) via digital communications. We have paid this Influencer one hundred five dollars USD.

COMPENSATION

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 07/06/2020 and ending on 07/10/2020 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid twelve thousand five hundred dollars USD via bank wire transfer.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 12/02/2020 and ending on 12/15/2020 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid an additional fifty thousand dollars USD via bank wire transfer. We own zero shares of (BSGM:US). To date we have been paid sixty two thousand five hundred dollars USD via bank wire transfer. To disseminate information about (BSGM:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 12/11/2020 and ending on 12/15/2020 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid an additional fifteen thousand dollars USD via bank wire transfer. We own zero shares of (BSGM:US). To date we have been paid seventy seven thousand five hundred dollars USD via bank wire transfer. To disseminate information about (BSGM:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 01/01/2021 and ending on 01/18/2021 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid an additional fifteen thousand dollars USD via bank wire transfer. We own zero shares of (BSGM:US). To date we have been paid ninety two thousand five hundred dollars USD via bank wire transfer. To disseminate information about (BSGM:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 02/02/2021 and ending on 02/03/2021 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid an additional ten thousand dollars USD via bank wire transfer. We own zero shares of (BSGM:US). To date we have been paid one hundred two thousand five hundred dollars USD via bank wire transfer. To disseminate information about (BSGM:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 02/04/2021 and ending on 03/31/2021 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid an additional twenty five thousand dollars USD via bank wire transfer. We own zero shares of (BSGM:US). To date we have been paid one hundred twenty seven thousand five hundred dollars USD via bank wire transfer. To disseminate information about (BSGM:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 04/01/2021 and ending on 05/07/2021 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid an additional fifty thousand dollars USD via bank wire transfer. We own zero shares of (BSGM:US). To date we have been paid one hundred seventy seven thousand five hundred dollars USD via bank wire transfer. To disseminate information about (BSGM:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 06/28/2021 and ending on 07/12/2021 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid an additional twenty five thousand dollars USD via bank wire transfer. We own zero shares of (BSGM:US). To date we have been paid two hundred two thousand five hundred dollars USD via bank wire transfer. To disseminate information about (BSGM:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 07/13/2021 and ending on 07/26/2021 to publicly disseminate information about (BSGM:US) via digital communications. We have been paid an additional twenty five thousand dollars USD via bank wire transfer. We own zero shares of (BSGM:US). To date we have been paid two hundred twenty seven thousand five hundred dollars USD via bank wire transfer. To disseminate information about (BSGM:US) via digital communications.

Disclaimer

Privacy Policy